NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

By Nikita Chaurasia  Date: 2020-08-03

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...